Empire Genomics Partners with Quadpharma to Manufacture ASRs2014-08-20 15:00:37
cGMP products are manufactured to meet Empire customer requirements
Date: August 20, 2014
Buffalo, New York - Empire Genomics, LLC, (www.empiregenomics.com), a leading molecular diagnostics company in the field of personalized cancer medicine, and QuaDPharma, (www.qdpharma.com), a rapidly growing commercial contract manufacturer, announced the completion of the first batch of GMP manufactured products.
Empire Genomics and QuaDPharma have formed an alliance to meet the growing demand for cGMP manufacturing for ASR (analyte-specific reagents) applications within the research, clinical, pharmaceutical industries. In order to meet test performance requirements, clients increasingly request that more stringent quality controls be applied to the earliest phases of their R&D and clinical services. Empire Genomics sought to meet this demand by leveraging the expertise of QuaDPharma.
“This relationship is critical in continuing to ensure that we meet the needs of our customers from research through clinical trials and ultimately the launching of companion diagnostic tests. This is the first phase and ultimately we expect to work with QDP to manufacture IVD products as well in the future. It was quite fortuitous to find such an experienced contract manufacturing group right in our back yard,” says Anthony Johnson, Empire Genomics President and CEO.
"We are excited at the prospect of applying our unique value added services to such an innovative and industry leading company. It also highlights the often-underrated advanced manufacturing capabilities resident to the Western New York region. This strategic partnership is also a good example of the diversity in our capabilities as an FDA regulated contract manufacturer." says Stephen Panaro, QuaDPharma President and CEO.